|
Age, years
|
|
Mean
|
51
|
51
|
53
|
49
|
|
Range
|
28–67
|
40–67
|
36–64
|
28–63
|
|
ECOG performance status
|
|
0
|
18
|
66.7
|
8
|
88.9
|
5
|
55.6
|
5
|
55.6
|
|
1
|
9
|
33.3
|
1
|
11.1
|
4
|
44.4
|
4
|
44.4
|
|
Level of HER2/neu overexpression
|
|
2+
|
8
|
29.6
|
3
|
33.3
|
2
|
22.2
|
3
|
33.3
|
|
3+
|
19
|
70.4
|
6
|
66.7
|
7
|
77.8
|
6
|
66.7
|
|
Receptor status
|
|
Estrogen receptor-positive (n = 26)
|
14
|
53.8
|
4
|
44.4
|
3
|
37.5
|
7
|
77.7
|
|
Progesterone receptor-positive (n = 26)
|
9
|
34.6
|
3
|
33.3
|
2
|
25.0
|
4
|
44.4
|
|
Menopausal status
|
|
Premenopausal
|
7
|
25.9
|
1
|
11.1
|
3
|
33.3
|
3
|
33.3
|
|
Postmenopausal
|
18
|
66.7
|
6
|
66.7
|
6
|
66.7
|
6
|
66.7
|
|
Perimenopausal
|
2
|
7.4
|
2
|
22.2
|
0
| |
0
| |
|
No. of metastatic sites
|
|
1
|
10
|
37.0
|
2
|
22.2
|
4
|
44.4
|
4
|
44.4
|
|
2
|
6
|
22.2
|
2
|
22.2
|
2
|
22.2
|
2
|
22.2
|
|
≥3
|
11
|
40.7
|
5
|
55.6
|
3
|
33.3
|
3
|
33.3
|
|
Dominant site of metastasis
|
|
Bone
|
15
|
55.6
|
5
|
55.6
|
4
|
44.4
|
6
|
66.7
|
|
Lymph node
|
12
|
44.4
|
5
|
55.6
|
4
|
44.4
|
3
|
33.3
|
|
Viscera
|
10
|
37.0
|
5
|
55.6
|
2
|
22.2
|
3
|
33.3
|
|
No. of prior chemotherapy regimens for metastatic disease
|
|
None
|
8
|
29.6
|
0
| |
3
|
33.3
|
5
|
55.6
|
|
1
|
14
|
51.9
|
5
|
55.6
|
6
|
66.7
|
3
|
33.3
|
|
2
|
5
|
18.5
|
4
|
44.4
|
0
| |
1
|
11.1
|
|
Prior hormonal therapy
|
13
|
48.1
|
8
|
88.9
|
2
|
22.2
|
3
|
33.3
|
|
Prior radiotherapy
|
15
|
55.6
|
4
|
44.4
|
6
|
66.7
|
5
|
55.6
|
